Pure Global

DiaPlexQTH Novel Coronavirus Detection Kit(DiaPlexQTH Novel Coronavirus Detection Kit)-The DiaPlexQ™ Novel Coronavirus Detection Kit is a real-time reverse transcriptase - India CDSCO Medical Device Registration

DiaPlexQTH Novel Coronavirus Detection Kit(DiaPlexQTH Novel Coronavirus Detection Kit)-The DiaPlexQ™ Novel Coronavirus Detection Kit is a real-time reverse transcriptase is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2020/000805_9371960df89b60bced46c15e384b9cda_c823f07abd72f8308dbaf935872032dd. This device is marketed under the brand name 2019-nCoV. The license holder is Bi-Biotech India Pvt Ltd, and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
DiaPlexQTH Novel Coronavirus Detection Kit(DiaPlexQTH Novel Coronavirus Detection Kit)-The DiaPlexQ™ Novel Coronavirus Detection Kit is a real-time reverse transcriptase
UID: IMP/IVD/2020/000805_9371960df89b60bced46c15e384b9cda_c823f07abd72f8308dbaf935872032dd

Brand Name

2019-nCoV

Device Class

Class C

Approving Authority

CDSCO

Product Information

PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal (2019-nCoV) swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal aspirates, nasal washes, bronchoalveolar lavage (2019-nCoV) fluid and sputum from individuals suspected of COVID-19 by their healthcare provider. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Other Products from Bi-Biotech India Pvt Ltd
Products from the same license holder (1 products)